Sivem Pharmaceuticals ULC Ranitidine Product Recall (2019-09-24)
· Published by Health Canada · Official notice
Alert type: Drug Recall
Category: Drugs
Issue: Product Safety
Audience: General Public, Healthcare Professionals, Hospitals
Department: Health Canada
Hazard classification: Type I
| Lot or serial number | Brand name | Companies | DIN, NPN, DIN-HIM | Dosage form | Strength |
|---|
| NP4177, NP4180, NT1365, PX8854 | B. Sivem Ranitidine 300 mg | - Recalling Firm
- Sivem Pharmaceuticals ULC
- 4705 Dobrin Street
- Saint-Laurent
- H4R 2P7
- Quebec
- CANADA
- Marketing Authorization Holder
- Sivem Pharmaceuticals ULC
- 4705 Dobrin Street
- Saint-Laurent
- H4R 2P7
- Quebec
- CANADA
| DIN 02385961 | Tablet | Ranitidine hydrochloride 300 mg |
| NP4183, NT2757, NT2764, NT2765, PJ2435, NP4184, NT2724, NT2762, NT2763, NP4179, NP5656, NP5657, NT2721, NT2722, PJ2434, PV6243, PV6244, PV6245 | A. Sivem Ranitidine 150 mg | - Recalling Firm
- Sivem Pharmaceuticals ULC
- 4705 Dobrin Street
- Saint-Laurent
- H4R 2P7
- Quebec
- CANADA
- Marketing Authorization Holder
- Sivem Pharmaceuticals ULC
- 4705 Dobrin Street
- Saint-Laurent
- H4R 2P7
- Quebec
- CANADA
| DIN 02385953 | Tablet | Ranitidine hydrochloride 150 mg |
A. Sivem Ranitidine 150 mg
B. Sivem Ranitidine 300 mg
Affected lots may be manufactured with an API containing an impurity, N-nitrosodimethylamine (NDMA).
Wholesalers, Healthcare Establishments, Retailers